AbbVie, a biopharmaceutical company, recently announced new results from the double-blind extension phase of the CELEST Phase 2 study in Crohn’s disease. Data show that many patients treated with upadacitinib who achieved a clinical response after the 16-week induction phase maintained the response to the treatment after the 36-week extension phase; the results observed for the higher doses (6 mg and 12 mg twice a day) were numerically greater than 3 mg twice a day at 52 weeks. The CELEST study evaluated upadacitinib, an experimental oral JAK1 selective inhibitor, in adult patients with active Crohn’s disease and inadequate response to an immunomodulator or alpha tumor necrosis factor antagonist (TNF-a). These data were presented at the 13th Congress of the European Crohn’s and Colitis Organization (ECCO) in Vienna.

LEAVE A REPLY

Please enter your comment!
Please enter your name here